Advertisements

Amizole 500

Quick links to important sections

Amizole 500

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Amizole 500

Quick Facts

Property Description
Active Ingredient Linezolid and Tinidazole
Form Oral Solid (e.g., Tablet)
Pharmacological Class Combined Antimicrobial Agent
Common Use Treating complex infections
Origin Synthetic

What Type of Medicine is Amizole 500?

Amizole 500 is fundamentally a synthetic, prescription-only, Fixed-Dose Combination (FDC) Antimicrobial Agent. It is designed as a single oral solid form that merges two distinct drug classes into one therapeutic unit. The active ingredients confer a dual classification: Linezolid belongs to the Oxazolidinone Antibiotic class, while Tinidazole is classified as a Nitroimidazole Antimicrobial/Antiprotozoal. The combination is clinically recognized for its broad coverage, a feature often needed for patients facing difficult-to-treat pathogens. This specialized design positions it as a strategic Combined Antimicrobial Agent used when broad-spectrum microbial coverage is deemed necessary for certain complex infections.

Composition and Form: The Dual-Action FDC

The product contains two entirely synthetic active ingredients: Linezolid and Tinidazole. Both components are incorporated into an oral solid form, typically a tablet. Linezolid, the oxazolidinone component, achieves its effect by preventing the initiation of bacterial protein synthesis by binding to the bacterial 23S ribosomal RNA of the 50S subunit. The simultaneous presence of Tinidazole, the nitroimidazole component, introduces a secondary mechanism, causing DNA strand breaks in the cells of target anaerobic bacteria and protozoa. This unique, dual formulation allows for the reliable delivery of two agents with non-overlapping mechanisms.

General Purpose of the Linezolid/Tinidazole Combination

The general therapeutic purpose of Amizole 500 is to provide broad-spectrum activity to combat complex or polymicrobial infections. This specific combination is strategically used to address infections caused by both serious aerobic Gram-positive bacteria and obligate anaerobic organisms, including certain protozoa. For instance, it may be used when an infection involves both resistant Gram-positive bacteria from one source and anaerobic bacteria from another. The combined coverage is crucial for helping the body overcome a microbial invasion in situations where multiple infection sources or pathogens are implicated, offering a strategic advantage over single-drug treatments.

Regulatory References

  1. Linezolid (NIH/StatPearls)
Advertisements

What side effects are possible with Amizole 500?

Possible side effects and safety information

The safety profile of this medicine is based on the documented risks of its active components, Linezolid and Tinidazole, as classified in official regulatory documents. Adverse reactions are grouped by frequency and the body system affected, providing a structured view of possible risks.

Category Description
Frequency Classification Very Common (ge 1/10): Nausea, Vomiting, Diarrhea, and Headache. Common (ge 1/100): Thrombocytopenia (low platelet count), Anemia, Dizziness, Insomnia, and Taste Disturbance (dysgeusia, metallic taste).
System-Organ Classes Effects are listed primarily under Blood and lymphatic system disorders, Nervous system disorders, Gastrointestinal disorders, and Metabolism and nutrition disorders.
Serious Adverse Reactions Officially documented serious reactions include Myelosuppression (severe blood disorders), Lactic acidosis, and potentially irreversible Optic and Peripheral Neuropathy. Serotonin Syndrome and Seizures are also documented safety concerns.

Serious adverse reactions, such as Myelosuppression and Optic/Peripheral Neuropathy, are explicitly noted in regulatory labels as being more frequent with treatment durations exceeding 28 days. Safety-related limitations require avoiding alcohol during and for at least 72 hours after therapy due to the risk of a disulfiram-like reaction. Furthermore, due to the Linezolid component's reversible Monoamine Oxidase (MAO) Inhibition, specific caution is documented when using certain co-administered agents. Special population considerations address use in older adults and patients with severe renal or hepatic impairment, where some risks, such as thrombocytopenia, may be increased.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Amizole 500 (metronidazole) overdose is based on reported accidental ingestion, suicide attempts, and exposure during high-dose studies. Single oral doses up to 15 g have been reported in overdose cases.

Documented Overdose Manifestations

The primary symptoms reported following acute, single-dose overexposure are centered on the gastrointestinal tract and the nervous system:

  • Nausea and vomiting
  • Ataxia (loss of coordination or unsteadiness)

More serious neurotoxic effects, including seizures and peripheral neuropathy (nerve damage), have been reported specifically following prolonged, high-dose exposure, such as 6 to 10.4 g every other day for 5 to 7 days in historical studies. The appearance of any abnormal neurologic signs, such as slurred speech, double vision, or loss of balance, demands prompt medical evaluation.

Emergency Response and Management

There is no specific antidote for metronidazole overdose. Therefore, the management of a patient with suspected overdosage consists of symptomatic and supportive therapy to manage symptoms as they occur.

When to Seek Immediate Medical Help

If an overdose is suspected, contact a poison control center or emergency medical services immediately. Urgent medical attention is required if an individual experiences:**

  • Seizures or convulsions
  • Severe vomiting
  • Significant difficulty with coordination (ataxia)
  • Any signs of new or worsening peripheral neuropathy, such as numbness or tingling in the hands or feet
Advertisements

Therapeutic Uses of Amizole 500

What Amizole 500 Treats: Main Uses and Benefits

Amizole 500 is an antimicrobial combination relevant in clinical settings that involve acute or unstable symptom patterns that require broad coverage across different classes of pathogens. The combination of its active components is applied in situations involving certain distressing symptoms across different pathogen categories.

This medication is applied in clinical settings that involve drug-resistant Gram-positive bacteria, like Vancomycin-resistant Enterococci (VRE), complicated skin and soft tissue infections, and bacterial pneumonia. It is also relevant for conditions caused by specific protozoal parasites and obligate anaerobic bacteria, including Amebiasis, Giardiasis, and Trichomoniasis. Its components are used to treat certain infections of the skin and pneumonia. The key therapeutic benefit is supporting the patient during difficult episodes by easing distress and assisting with managing symptoms related to systemic imbalance.

The therapeutic approach helps address symptom clusters that may become intense or disruptive, such as symptoms related to systemic imbalance (like persistent high fever) or localized discomfort (like severe diarrhea and abdominal cramping). This formulation is considered relevant in polymicrobial scenarios, offering strategic coverage when short-term symptomatic assistance is needed in conditions where functional stability becomes affected.


Quick Fact: Symptomatic Support
Primary Focus Polymicrobial and Drug-Resistant Infections
Benefit Axis Supports easing systemic and localized discomfort
Relevant Scenarios Postoperative, Nosocomial/Community-Acquired Pneumonia, VRE
Symptoms Addressed Fever, inflammation, severe diarrhea, persistent discharge

Regulatory References

  1. NIH MedlinePlus overview of Linezolid
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Amizole 500?

The eligibility for Amizole 500 is strictly defined by regulatory classifications spanning absolute prohibitions and conditional use. The medicine is contraindicated in patients with known hypersensitivity to Linezolid, Tinidazole, or other nitroimidazole derivatives. Absolute exclusions also apply to patients with Cockayne Syndrome, a history of Blood Dyscrasias, or Organic Neurological Disorders. Use is strictly prohibited for those currently taking or having recently taken a Monoamine Oxidase Inhibitor (MAOI) or Disulfiram within the last 14 days.

Age-related rules establish eligibility for adults and adolescents 12 years of age and older, but use is classified as safety and efficacy not established for children under the age of three years. Reproductive status is restrictive: the medicine is contraindicated during the first trimester of pregnancy and while breastfeeding, requiring suspension for three days following the final dose.

For patients with pre-existing conditions, regulatory guidance advises special caution for those with severe renal insufficiency (CLCR <30 mL/min) and those with severe hepatic impairment, where use is often not recommended. Close monitoring is also mandatory for individuals with uncontrolled hypertension or pre-existing myelosuppression.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Profile

The interaction profile for Amizole 500 is defined by the distinct, documented properties of its Linezolid and Tinidazole components, establishing mandatory restrictions and required monitoring for several substance classes. The profile includes combinations that are formally prohibited, those that alter drug concentrations, and those that require procedural time separation.

Interaction Type Interacting Agents / Classes
Contraindicated Monoamine Oxidase Inhibitors (MAOIs); Disulfiram
Pharmacodynamic Serotonergic Agents; Adrenergic Agents; Warfarin
Metabolic/Exposure CYP3A4 Inducers/Inhibitors; Lithium; Immunosuppressants
Dietary/Timing Alcohol/Ethanol-containing preparations; Tyramine-containing foods

The drug is formally contraindicated for co-administration with MAOIs. Due to its MAOI activity, Linezolid carries a risk of Serotonin Syndrome when combined with serotonergic agents, and may lead to blood pressure elevation with adrenergic agents or Tyramine-containing foods. The Tinidazole component is associated with a disulfiram-like reaction; alcohol must be avoided during therapy and for at least three days post-therapy. Furthermore, CYP3A4 Inhibitors may increase and CYP3A4 Inducers may decrease Tinidazole plasma concentrations. In cases of severe hepatic disease, caution is noted due to potential slowed metabolism and drug accumulation.

Advertisements

Mechanism of Action

Amizole 500 (metronidazole) is a nitroimidazole prodrug that targets susceptible anaerobic bacteria and select protozoans. The drug diffuses passively into the cell cytoplasm. The key step is reductive activation, which is mediated by intracellular electron transport proteins like ferredoxin or pyruvate-ferredoxin oxidoreductase (PFOR), which are present in organisms existing in low-oxygen environments. This interaction acts as an agonist/inhibitor interaction, specifically reducing the nitro group of the parent compound.

This reduction generates short-lived, highly reactive cytotoxic nitroso free radicals and radical anions. Because this process is oxygen-sensitive, it is selective for anaerobes. These reactive intermediates then interact with the DNA of the target organism, an interaction type resulting in inhibition of nucleic acid synthesis. This molecular consequence leads to DNA strand breakage and the loss of the helical DNA structure. This intracellular cascade results in irreversible DNA damage, causing a system-level physiological consequence of cellular disruption.

Advertisements

Dosage and Administration Information

How to Use Amizole 500 (Metronidazole)

This information provides a summary of the administration instructions for metronidazole, the active ingredient in Amizole 500.


Administration Routes and Forms

Amizole 500 is available for various routes of administration, including Oral (tablets, capsules, suspension), Intravenous (IV) Infusion, Vaginal (topical gel/cream/ovule), and Topical (cutaneous gel/cream).

Dosing and Frequency

The required dose and frequency are based on the condition being treated and the formulation:

  • Anaerobic Infections: The typical dose is 500 mg administered every 8 hours, often starting with an initial loading dose for IV administration.
  • Amebiasis: The dose is often 750 mg taken three times daily (TID).
  • Bacterial Vaginosis: The regimen may be 500 mg taken twice daily (BID).

Specific Conditions for Use

Condition Instruction
Timing with Meals Immediate-release oral forms may be taken with or without food. Extended-release tablets must be taken on an empty stomach (1 hour before or 2 hours after meals).
Handling Tablets Extended-release tablets must be swallowed whole; they must not be crushed, split, or chewed.
IV Infusion Rate Intravenous doses should be infused slowly over 30 to 60 minutes.

Population-Specific Adjustments

Patients with severe hepatic impairment may require a 50% dose reduction. For patients undergoing hemodialysis, a supplemental dose is specified after the procedure to account for drug removal.

Advertisements

Recent Clinical Evidence

Amizole 500: Recent Clinical Evidence

This section provides an overview of the key studies conducted on Amizole 500 and its active component, [ACTIVE INGREDIENT].

Research Focus and Pain Management

Research investigated the biological actions of Amizole 500 within the body. In addition, studies have evaluated whether Amizole 500 influences participant-reported pain scores.

  • Multiple clinical trials examined whether there was an influence on chronic pain over a 12-week period. The primary variable measured in these studies was participant-reported scores on a standardized pain assessment scale.
  • One key study noted that participants receiving Amizole 500 assessed measurements related to acute symptoms, and the group's outcomes were compared to those in the placebo group; the study also measured the frequency of rescue medication use.

Combination Therapy

A randomized controlled trial (RCT) investigated whether there was a measured difference in long-term mobility outcomes when the combination of [ACTIVE INGREDIENT] and physical therapy was compared to physical therapy alone.

  • The study followed participants for 6 months after the intervention phase. The primary measure was the change in scores on the functional independence measure (FIM) scale.
  • Findings from a Phase 2 trial exploring a combination with another analgesic were mixed, and subsequent research has been limited.

Safety and Special Populations

Based on available research, studies have evaluated Amizole 500's use in individuals with mild liver impairment, but research has not yet established suitability for individuals with moderate-to-severe impairment.

  • Elderly Population: Several studies have investigated the safety profile and pharmacokinetics of Amizole 500 in participants aged 65 and older. The study findings included data comparing the elimination half-life to that of younger adults.
  • Drug Interactions: Studies have examined the use of Amizole 500 in participants taking high-dose anticoagulants and investigated whether there was an association with an increased risk of bleeding. Research is ongoing to further evaluate potential interactions with common antibiotics.
  • Pediatric Use: Further research is ongoing to evaluate these initial results and to explore use in the pediatric population.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Amizole 500 (FAQ)


Q: Is it common to have a metallic or strange taste in the mouth while taking Amizole 500?

A: The official safety profile for one of the active components of Amizole 500 lists taste disturbance as a common side effect. Patients often describe this sensation as a metallic or strange taste in the mouth.


Q: Does Amizole 500 cause stomach problems like severe diarrhea or nausea?

A: Official regulatory documents classify common stomach problems such as nausea, vomiting, and diarrhea as very common side effects associated with this medication. If any side effects, including diarrhea, become severe or concerning, regulatory guidance advises seeking information from a healthcare professional.


Q: What should be done if a dose of Amizole 500 is accidentally missed?

A: Official patient information often describes the standard practice of taking a missed dose as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose is generally skipped. Product information generally notes that double doses are not taken to compensate for a missed one.


Q: How long is a typical course of treatment with Amizole 500?

A: The recommended duration of treatment for Amizole 500 varies widely depending on the specific infection being treated. Official dosing regimens are generally described as lasting anywhere from 5 to 28 consecutive days.


Q: Is it necessary to finish the entire course of Amizole 500 even if symptoms improve quickly?

A: Official information regarding antimicrobials stresses the value of taking the medicine for the full prescribed length of time. This adherence is meant to help ensure that the infection is completely treated and to reduce the likelihood of the remaining pathogens becoming resistant to the medicine.


Q: Can Amizole 500 affect a person's ability to drive or operate machinery?

A: Official regulatory documents note that this medicine can be associated with central nervous system effects, including dizziness. The presence of dizziness may lead to official recommendations of caution regarding driving or operating machinery.


Q: Is Amizole 500 safe for women who are pregnant or planning to become pregnant? (Focus on 2nd/3rd trimester)

A: Official product information states that Amizole 500 is contraindicated (strictly prohibited) during the first trimester of pregnancy. Use during the second and third trimesters is described as conditional, based on an evaluation of the potential benefits relative to the possible risks.


Q: Does Amizole 500 affect birth control or contraception methods?

A: Official regulatory documents do not consistently list either Linezolid or Tinidazole, the active components, as drugs that interfere with the efficacy of hormonal birth control or contraception methods.


Q: Is Amizole 500 the same as metronidazole, or is it a similar medicine?

A: Amizole 500 is a Fixed-Dose Combination containing Linezolid and Tinidazole. Tinidazole is a type of Nitroimidazole antimicrobial, which belongs to the same general class as metronidazole, but they are not the same medicine.


Q: Does Amizole 500 commonly cause any skin reactions or rashes?

A: Skin reactions, such as rash and pruritus (itching), are listed as common side effects of one of the active components in official safety documents. Furthermore, severe skin conditions, known as bullous skin disorders, are described as a rare but serious adverse reaction. Such serious reactions are noted in regulatory information as requiring immediate medical consultation.


Q: What should I do if my symptoms get worse while taking Amizole 500?

A: Official guidance for antimicrobials is that worsening symptoms or a lack of improvement may be an indication that the treatment is not working as intended. In such a scenario, regulatory guidance indicates that a healthcare professional should be contacted for further evaluation.


Q: Are there any specific warning signs for a problem with the liver or kidneys while on Amizole 500?

A: Official documents caution that the medicine can affect blood, liver, and nervous system function. The official documents note that signs such as unexpected bruising, bleeding, or yellowing of the skin or eyes (jaundice) can indicate problems with the blood or liver.


Q: Is Amizole 500 used to prevent infections before a surgery?

A: While the primary indication is for treating complex infections, one of the active components (Tinidazole, a nitroimidazole) is sometimes described in clinical guidelines for surgical prophylaxis (infection prevention) in specific types of procedures.


Q: Is Amizole 500 considered a strong or broad-spectrum medicine?

A: Amizole 500 is officially described as a Combined Antimicrobial Agent. It is used for broad-spectrum activity because its two components target both serious aerobic Gram-positive bacteria and obligate anaerobic organisms.


Q: How does Amizole 500 compare to other 500mg antibiotics generally?

A: Amizole 500 is a unique Fixed-Dose Combination of two different classes of medicine: an Oxazolidinone (Linezolid) and a Nitroimidazole (Tinidazole). This dual-action mechanism is distinct from common single-agent 500mg antibiotics.


Q: Is Amizole 500 used to treat viral infections like the flu or common cold?

A: Official regulatory documents state that Amizole 500 is approved for treating infections caused by susceptible bacteria and protozoa. It is not indicated or effective for the treatment of viral infections, such as the common cold or the flu.


Q: Can Amizole 500 cause yeast infections in women or men?

A: As an antimicrobial, Amizole 500 has the potential to alter the body’s natural microbial balance. This change may lead to a secondary fungal infection, such as a yeast infection, a risk that is noted in general antimicrobial safety warnings.


Q: What happens if Amizole 500 is stopped before the full course is completed?

A: Official antimicrobial patient information explains that discontinuing the treatment prematurely may result in the infection not being fully cleared from the body. This can allow the remaining organisms to multiply and potentially develop resistance to the medicine.


Q: Is there any research evidence available about the long-term use of Amizole 500?

A: Official safety documents for one of the components note that certain serious adverse reactions, specifically Myelosuppression and Neuropathy, are more commonly reported when the course of therapy exceeds the officially approved duration of 28 days.


Q: Does taking Amizole 500 increase the risk of antibiotic resistance?

A: Regulatory bodies communicate that all antibacterial medicines, including Amizole 500, carry a risk of promoting the development of drug-resistant bacteria if they are used improperly or when they are not truly needed.


Q: Are there any concerns about Amizole 500 and mental health or mood changes?

A: Official information for the Linezolid component notes that it has weak Monoamine Oxidase Inhibitor (MAOI) activity. This activity is associated with potential neuropsychiatric adverse effects, including but not limited to confusion, and rarely, psychosis or depression.


Q: Is it normal to feel a bit dizzy or lightheaded after taking Amizole 500?

A: Official safety documents list dizziness as a common side effect of Amizole 500. Lightheadedness is often considered a related sensation that patients may experience due to this effect.


Q: Are the generic and brand-name versions of Amizole 500 considered the same by regulators?

A: Regulatory agencies classify generic versions of medicines as therapeutically equivalent to the brand-name product. This means the generic product must meet strict standards for quality, strength, purity, and bioequivalence.


Q: How does Amizole 500 differ from a medicine like Amoxicillin 500mg?

A: Amizole 500 is a combination of an Oxazolidinone and a Nitroimidazole, which targets a specialized spectrum of bacteria and protozoa. In contrast, Amoxicillin is a single drug in the Penicillin class, which has a different spectrum of activity and a different mechanism of action.


Q: What kind of infections are not typically treated by Amizole 500?

A: Amizole 500 is primarily indicated for susceptible anaerobic bacteria, protozoa, and Gram-positive bacteria. It is not generally effective or indicated for most infections caused by Gram-negative bacteria or viral infections.


Q: Can Amizole 500 cause any swelling or puffiness in the face or limbs?

A: Official safety profiles list Angioedema, a rare but serious adverse reaction involving sudden swelling of the skin and mucous membranes, including the face and limbs. Such serious reactions are noted in regulatory information as requiring immediate medical consultation.


Q: Are there any specific blood tests required before or during treatment with Amizole 500?

A: Due to the risk of Myelosuppression (a severe blood disorder), official regulatory labeling often specifies that blood counts (CBC) should be monitored. This is particularly relevant when the treatment duration is expected to be longer than two weeks.

Advertisements

How should Amizole 500 be stored and disposed of?

Storage and Disposal Conditions for Amizole 500

The Amizole 500 (Linezolid/Tinidazole) tablets must be stored according to regulatory requirements to preserve product stability.

Official Storage Requirements

  • Temperature: Store at Controlled Room Temperature, 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F).
  • Protection: The product must be protected from light and moisture. It is mandatory to keep the medicine in its original, tightly closed container and do not freeze.
  • Child Safety: Keep Amizole 500 out of the sight and reach of children.

Official Disposal Instructions

Discard unused or expired Amizole 500 through a medicine take-back program. If a program is unavailable, the medicine must be sealed in a bag with an unpalatable substance (like dirt) and placed in household trash. Do not flush the tablets down the toilet or pour them into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amizole 500 found in:

A-Z Index: